MDGL - シンタ・ファ―マシュ―ティカルズ (Madrigal Pharmaceuticals Inc.) シンタ・ファ―マシュ―ティカルズ

 MDGLのチャート


 MDGLの企業情報

symbol MDGL
会社名 Madrigal Pharmaceuticals Inc (シンタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マドリガル・ファーマシューティカルズ(Madrigal Pharmaceuticals Inc)(旧名:Synta Pharmaceuticals Corp.)は臨床病期のバイオ医薬品会社である。同社は心血管代謝疾患および非アルコール性脂肪性肝炎(NASH)の治療用の治療候補の開発・商業化に従事する。主力製品であるMGL-3196は、NASHの治療用第Ⅱ相準備の1日1回、経口、肝臓特異的選択甲状腺ホルモン受容体-b(THR-b)アゴニスト、および異型接合性および同型接合性家族性高コレステロール血症(FH)である。その製品パイプラインには、NASHとFHの治療に使用されるMGL-3745も含まれる。MGL-3196は、健康なボランティアで第I相単回投与および複数回投与試験を完了し、低密度リポタンパク質コレステロール、トリグリセリドレベルおよびリポタンパク質(a)を低下させるための異常脂質血症/高コレステロール血症のために開発されている。また、脂肪代謝を増加させることによって血漿・肝臓中のトリグリセリドを減少させ、抗糖尿病作用を示す。   シンタ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。主にがんや慢性炎症性疾患などの、重篤な病状や患者のための小分子薬の発見・開発・製品化に取り組む。臨床段階のがんの候補薬や、前臨床段階の炎症性疾患治療薬の開発プログラムを保有する。本社はマサチュ―セッツ州レキシントン。   Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)-ß and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR-ß agonism. The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly ß-selective THR agonist.
本社所在地 Four Tower Bridge 200 Barr Harbor Drive Suite 400 West Conshohocken PA 19428 USA
代表者氏名 Paul A. Friedman ポール・A・フリードマン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 404-380-9263
設立年月日 36586
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 8人
url www.syntapharma.com
nasdaq_url https://www.nasdaq.com/symbol/mdgl
adr_tso
EBITDA EBITDA(百万ドル) -32.32700
終値(lastsale) 199.3138
時価総額(marketcap) 3062782215.7492
時価総額 時価総額(百万ドル) 2957.77
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 2467.465
当期純利益 当期純利益(百万ドル) -29.63200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Madrigal Pharmaceuticals Inc revenues was not reported. Net loss decreased 11% to $12.8M. Lower net loss reflects Interest income increase from $168K to $1.9M (income) Research and development decrease of 16% to $9.2M (expense) General and administrative decrease of 2% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.20 to -$0.90.

 MDGLのテクニカル分析


 MDGLのニュース

   Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundations Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)  2021/10/04 10:50:00 Intrado Digital Media
In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH
   Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation''s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)  2021/10/04 10:50:00 Benzinga
CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ: MDGL ), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver Foundation, the leading patient advocacy organization focused on the diagnosis, treatment and support of Americans with non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH). Today, Madrigal and the Fatty Liver Foundation will ring the Nasdaq closing bell to raise awareness of the need for more evidence-based screening and testing to improve diagnosis and staging of NAFLD/NASH. NAFLD is estimated to afflict more than 16 million Americans. NASH is the more severe form of NAFLD. There are more than 5 million NASH patients with significant fibrosis in the U.S. Once NASH progresses to significant liver fibrosis, the risk of adverse liver outcomes increases dramatically. In fact, NASH is currently the leading cause of liver transplants in the U.S.
   Madrigal Pharmaceuticals Inc (MDGL): Price Now Near $80.61; Daily Chart Shows Downtrend on 100 Day Basis  2021/09/13 15:18:51 ETF Daily News
If you''re a trend trader, consider that the strongest clear trend on the daily chart exists on the 50 day timeframe. The post Madrigal Pharmaceuticals Inc (MDGL): Price Now Near $80.61; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .
   The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi''s Pemphigus Trial Disappointment, Humanigen''s COVID-19 Drug Denied Emergency Use Authorization  2021/09/09 12:17:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE: ABT ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced its quarterly results) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) ICU Medical, Inc. (NASDAQ: ICUI ) (announced a deal to buy Smiths Medical division for $2.35 billion in cash) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Kadmon Holdings, Inc. (NASDAQ: KDMN ) - announced a deal to be bought by Sanofi (NASDAQ: SNY ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Medtronic plc (NYSE: MDT ) MiMedx Group, Inc. (NASDAQ: MDXG ) Nuvalent, Inc. (NASDAQ: NUVL ) (announced its second-quarter results) Quest Diagnostics Incorporated (NYSE: DGX ) ResMed Inc.
   The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma  2021/08/12 12:09:26 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, Inc. (NASDAQ: RANI ) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Adicet Bio, Inc. (NASDAQ: ACET ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) Aptose Biosciences Inc.
   Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/03/04 15:26:33 Investing.com
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Madrigal Pharmaceuticals Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/23 14:56:00 Stock Market Daily
Madrigal Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   So Microcap Biotechs Is Where The Action Is Next...  2021/02/04 23:59:00 Zero Hedge
So Microcap Biotechs Is Where The Action Is Next… Earlier today we observed that just as the Gamestop short squeeze was finally fizzling with the buying frenzy turning to full-blown liquidation, which sent GME stock below $50 or down nearly 50% on the day... ... back to where it was trading on the Friday when Andrew Left capitulated to the r/wallstreetbets horde, a clear rotation was taking place, one which we last Friday predicted would take place... What's after the short squeeze slaughter: the pennystock pump? — zerohedge (@zerohedge) January 30, 2021 .... namely one out of the " most-shorted" names and into the "most-illiquid", microcap stocks as shown below. And while the waves of ramping were initially diffuse without a clear target, as the day progressed it emerged that the " reddit rebellion" was now targeting tiny biotech names (under $2 billion in market cap, hence illiquid enough where a group of retail daytraders could leave quite a mark) which while not having GME's absurd 140% short-to-float ratio were also quite shorted.
   B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/01/12 20:35:57 Investing.com
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc  2020/11/12 11:18:10 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/03/04 15:26:33 Investing.com
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Madrigal Pharmaceuticals Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/23 14:56:00 Stock Market Daily
Madrigal Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   So Microcap Biotechs Is Where The Action Is Next...  2021/02/04 23:59:00 Zero Hedge
So Microcap Biotechs Is Where The Action Is Next… Earlier today we observed that just as the Gamestop short squeeze was finally fizzling with the buying frenzy turning to full-blown liquidation, which sent GME stock below $50 or down nearly 50% on the day... ... back to where it was trading on the Friday when Andrew Left capitulated to the r/wallstreetbets horde, a clear rotation was taking place, one which we last Friday predicted would take place... What's after the short squeeze slaughter: the pennystock pump? — zerohedge (@zerohedge) January 30, 2021 .... namely one out of the " most-shorted" names and into the "most-illiquid", microcap stocks as shown below. And while the waves of ramping were initially diffuse without a clear target, as the day progressed it emerged that the " reddit rebellion" was now targeting tiny biotech names (under $2 billion in market cap, hence illiquid enough where a group of retail daytraders could leave quite a mark) which while not having GME's absurd 140% short-to-float ratio were also quite shorted.
   B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/01/12 20:35:57 Investing.com
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc  2020/11/12 11:18:10 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シンタ・ファ―マシュ―ティカルズ MDGL Madrigal Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)